CollPlant Biotechnologies (NASDAQ:CLGN) Earns “Buy” Rating from D. Boral Capital

CollPlant Biotechnologies (NASDAQ:CLGN)‘s stock had its “buy” rating reissued by analysts at D. Boral Capital in a report released on Thursday,Benzinga reports. They presently have a $14.00 price objective on the stock. D. Boral Capital’s price target would indicate a potential upside of 449.02% from the company’s previous close.

Separately, HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of CollPlant Biotechnologies in a research report on Friday, November 29th.

CollPlant Biotechnologies Trading Down 3.8 %

Shares of CLGN opened at $2.55 on Thursday. CollPlant Biotechnologies has a 12-month low of $2.54 and a 12-month high of $6.75. The company has a market cap of $29.21 million, a PE ratio of -1.66 and a beta of 1.07. The stock has a 50-day moving average price of $3.44 and a 200-day moving average price of $3.93.

CollPlant Biotechnologies (NASDAQ:CLGN) last announced its earnings results on Wednesday, March 26th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.08. CollPlant Biotechnologies had a negative net margin of 2,680.00% and a negative return on equity of 77.05%. The business had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.36 million. As a group, analysts predict that CollPlant Biotechnologies will post -1.44 earnings per share for the current year.

Institutional Trading of CollPlant Biotechnologies

Hedge funds and other institutional investors have recently bought and sold shares of the company. Benjamin Edwards Inc. purchased a new position in shares of CollPlant Biotechnologies during the third quarter worth approximately $112,000. AMH Equity Ltd grew its holdings in shares of CollPlant Biotechnologies by 17.4% during the 4th quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock valued at $419,000 after purchasing an additional 17,295 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of CollPlant Biotechnologies during the 4th quarter valued at $38,000. Finally, Wells Fargo & Company MN raised its position in CollPlant Biotechnologies by 110.1% in the 4th quarter. Wells Fargo & Company MN now owns 8,405 shares of the company’s stock worth $30,000 after purchasing an additional 4,405 shares during the period. Hedge funds and other institutional investors own 21.69% of the company’s stock.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.